Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Is CJC-1295 Legal in Louisiana? How to Access It Legally

By
Published Updated Last reviewed
9 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • FDA approval / None. FDA found no approved product containing any form of CJC-1295 in the 12 countries it searched or authorized by the European Medicines Agency [1]
  • FDA compounding lists / In none of the three categories for state-licensed pharmacies and physicians, and not on the outsourcing-facility list [2][3]
  • Advisory committee, December 2024 / 0 yes, 13 no on CJC-1295 free base; 1 yes, 12 no on acetate; 0 yes, 13 no on each DAC form [5]
  • Published human studies / Three, all of the DAC form, all in healthy volunteers [1]
  • Sport / WADA names CJC-1295 in S2.2.4, prohibited at all times [6]

Is CJC-1295 FDA-approved?

No. FDA found no approved product containing any form of CJC-1295 in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain or the United Kingdom, and none authorized by the European Medicines Agency [1]. CJC-1295 is an investigational long-acting analogue of growth hormone-releasing hormone (GHRH), developed by ConjuChem Biotechnologies of Montreal and first described in 2005 [1][7]. FDA describes two forms: CJC-1295, a 29-amino-acid GHRH analogue, and CJC-1295 DAC, the same peptide with an extra maleimidopropionic acid-lysine unit that lets it bind blood albumin and last much longer [1]. Sermorelin was once approved as Geref and withdrawn in 2009; CJC-1295 never was [1].

What has FDA said about compounding CJC-1295?

FDA's page on bulk substances that may present significant safety risks lists CJC-1295 in its 'nominated but withdrawn' table: it had been in category 2 for significant safety risks and came off when the nominators withdrew [8]. FDA's stated concerns remain posted: possible immunogenicity for certain routes, impurity and characterization problems, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data [8].

CJC-1295 is in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is not on the list for outsourcing facilities (updated March 21, 2025) [2][3]. The October 2026 HHS draft enforcement-discretion policy covers six other peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), not CJC-1295, and no other FDA or HHS action allowing its compounding has been identified [4].

What does this mean for compounding pharmacies?

CJC-1295 is not a component of an FDA-approved drug and has no USP monograph, so FDA's category 1 policy, which generally means no action against compounders that meet its conditions, does not apply to it [2][3]. In December 2024, FDA's Pharmacy Compounding Advisory Committee voted against adding each CJC-1295 form to the pharmacy bulks list [5].

What about products sold online?

FDA says CJC-1295 products sold online are mostly labeled 'research use only', including blends with ipamorelin and GHRPs, and that CJC-1295 has been found in illicit sports use [1]. A research-use-only product is not an FDA-approved drug [1].

Frequently asked questions

Is CJC-1295 legal in Louisiana?
CJC-1295 is not FDA-approved and is not on FDA's compounding lists, and no FDA or HHS action allowing its compounding has been identified [1][2][3][4].
Can a Louisiana pharmacy compound CJC-1295?
It is in none of the three categories on FDA's list for state-licensed pharmacies and physicians and is not on the outsourcing-facility list. The advisory committee voted against adding each form in December 2024 [2][3][5].
Are CJC-1295 products sold online FDA-approved?
No. FDA says products sold online are mostly labeled research use only, and research-use-only products are not FDA-approved drugs [1].
Does WADA ban CJC-1295?
Yes. WADA names CJC-1295 in S2.2.4 of its 2026 Prohibited List as a growth hormone-releasing hormone analogue, prohibited at all times in and out of competition, and it appears in the 2027 List too [6][9].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  4. Official web page. Official web page
  5. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  6. World Anti-Doping Agency. World Anti-Doping Agency
  7. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
  8. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  9. World Anti-Doping Agency. World Anti-Doping Agency
Evidence overview for Is CJC-1295 Legal in Louisiana? How to Access It Legally